VSNL1 Promotes Gastric Cancer Cell Proliferation and Migration by Regulating P2X3/P2Y2 Receptors and Is a Clinical Indicator of Poor Prognosis in Gastric Cancer Patients

Table 1

Relationship of VILIP-1 expression with pathological parameters of GC.

Clinical parameters	VILIP-1
	Low	High
Age (yrs)			-3.781	<0.01
Gender			0.081	0.776
Male	187 (60.1%)	124 (39.9%)
Female	77 (61.6%)	48 (38.4%)
Location			1.709	0.426
Proximal	29 (52.7%)	26 (47.3%)
Middle	102 (62.6%)	61 (37.4%)
Distal	133 (61.0%)	85 (39.0%)
Size			5.695	0.017
<5 cm	167 (65.2%)	89 (34.8%)
≥5 cm	97 (53.9%)	83 (46.1%)
Lauren classification			47	<0.01
Intestinal	170 (76.2%)	53 (23.8%)
Diffuse	94 (44.1%)	119 (55.9%)
Histology classification			2.656	0.448
Papillary adenocarcinoma	9 (56.2%)	7 (43.8%)
Tubular adenocarcinoma	192 (58.9%)	134 (41.1%)
Mucinous adenocarcinoma	21 (72.4%)	8 (27.6%)
Signet ring cell carcinoma	42 (64.6%)	23 (35.4%)
Histologic differentiation			3.336	0.343
Well	11 (84.6%)	2 (15.4%)
Moderately	77 (60.2%)	51 (39.8%)
Poorly	175 (59.7%)	118 (40.3%)
Others	1 (50%)	1 (50%)
Invasion depth			25.748	<0.01
T1	47 (82.5%)	10 (17.5%)
T2	77 (70.6%)	32 (29.4%)
T3	129 (52.9%)	115 (47.1%)
T4	11 (42.3%)	15 (57.7%)
Lymphatic metastasis			30.767	<0.01
No	128 (83.1%)	38 (16.9%)
Yes	136 (30.4%)	134 (69.6%)
Regional lymph nodes			32.746	<0.01
PN0	128 (77.1%)	38 (22.9%)
PN1	74 (54.4%)	62 (45.6%)
PN2	45 (45.5%)	54 (54.5%)
PN3	17 (48.6%)	18 (51.4%)
Distant metastasis			17.8	<0.01
No	242 (64.5%)	133 (35.5%)
Yes	22 (36.1%)	39 (63.9%)
TNM stages			45.868	<0.01
I	74 (82.2%)	16 (17.8%)
II	75 (72.1%)	29 (27.9%)
III	90 (52.0%)	83 (48.0%)
IV	25 (36.2%)	44 (63.8%)